Cargando…

Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial

BACKGROUND: This study tested whether early left intracoronary arterial (LAD) administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs, called OmniMSCs) in acute ST-segment elevation myocardial infarction (STEMI) of Lee-Sung pigs induced by 90 min balloon-occluded LAD was safe and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wannhsin, Hou, Chun-Hsiang, Chen, Yi-Ling, Shen, Hsin-Hsin, Lin, Chen-Hsuan, Wu, Cheng-Yi, Lin, Meng-Hsueh, Liao, Chih-Ching, Huang, Jun-Jae, Yang, Chi-Yu, Li, Yi-Chen, Yip, Hon-Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091140/
https://www.ncbi.nlm.nih.gov/pubmed/37063964
http://dx.doi.org/10.3389/fcvm.2023.1153428
_version_ 1785023091920863232
author Chen, Wannhsin
Hou, Chun-Hsiang
Chen, Yi-Ling
Shen, Hsin-Hsin
Lin, Chen-Hsuan
Wu, Cheng-Yi
Lin, Meng-Hsueh
Liao, Chih-Ching
Huang, Jun-Jae
Yang, Chi-Yu
Li, Yi-Chen
Yip, Hon-Kan
author_facet Chen, Wannhsin
Hou, Chun-Hsiang
Chen, Yi-Ling
Shen, Hsin-Hsin
Lin, Chen-Hsuan
Wu, Cheng-Yi
Lin, Meng-Hsueh
Liao, Chih-Ching
Huang, Jun-Jae
Yang, Chi-Yu
Li, Yi-Chen
Yip, Hon-Kan
author_sort Chen, Wannhsin
collection PubMed
description BACKGROUND: This study tested whether early left intracoronary arterial (LAD) administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs, called OmniMSCs) in acute ST-segment elevation myocardial infarction (STEMI) of Lee-Sung pigs induced by 90 min balloon-occluded LAD was safe and effective. METHODS AND RESULTS: Young male Lee-Sung pigs were categorized into SC (sham-operated control, n = 3), AMI-B (STEMI + buffer/21 cc/administered at 90 min after STEMI, n = 6), and AMI-M [acute myocardial infarction (AMI) + hBMMSCs/1.5 × 10(7)/administered at 90 min after STEMI, n = 6] groups. By 2 and 5 months after STEMI, the cardiac magnetic resonance imaging demonstrated that the muscle scar score (MSS) and abnormal cardiac muscle exercise score in the infarct region were significantly increased in the AMI-B than in the SC group that were significantly reversed in the AMI-M group, whereas the left ventricular ejection function by each month (from 1 to 5) displayed an opposite pattern of MSS among the groups (all p < 0.001). By 5 months, histopathological findings of infarct and fibrosis areas and isolectin-B4 exhibited an identical pattern, whereas the cellular expressions of troponin-I/troponin-T/von Willebrand factor exhibited an opposite pattern of MSS among the groups (all p < 0.001). The ST-segment resolution (>80%) was significantly earlier (estimated after 6-h AMI) in the AMI-M group than in the AMI-B group (p < 0.001). The protein expressions of inflammation (IL-1β/TNF-α/NF-κB)/oxidative stress (NOX-1/NOX-2/oxidized protein)/apoptosis (cleaved caspase-3/cleaved PARP)/DNA damage (γ-H2AX) displayed an identical pattern to MSS among the groups, whereas the protein expressions of angiogenesis factors (SDF-1α/VEGF) were significantly and progressively increased from SC, AMI-B, to AMI-M groups (all p < 0.001). CONCLUSION: Early intra-LAD transfusion of OmniMSC treatment effectively reduced the infarct size and preserved LV function in porcine STEMI.
format Online
Article
Text
id pubmed-10091140
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100911402023-04-13 Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial Chen, Wannhsin Hou, Chun-Hsiang Chen, Yi-Ling Shen, Hsin-Hsin Lin, Chen-Hsuan Wu, Cheng-Yi Lin, Meng-Hsueh Liao, Chih-Ching Huang, Jun-Jae Yang, Chi-Yu Li, Yi-Chen Yip, Hon-Kan Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: This study tested whether early left intracoronary arterial (LAD) administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs, called OmniMSCs) in acute ST-segment elevation myocardial infarction (STEMI) of Lee-Sung pigs induced by 90 min balloon-occluded LAD was safe and effective. METHODS AND RESULTS: Young male Lee-Sung pigs were categorized into SC (sham-operated control, n = 3), AMI-B (STEMI + buffer/21 cc/administered at 90 min after STEMI, n = 6), and AMI-M [acute myocardial infarction (AMI) + hBMMSCs/1.5 × 10(7)/administered at 90 min after STEMI, n = 6] groups. By 2 and 5 months after STEMI, the cardiac magnetic resonance imaging demonstrated that the muscle scar score (MSS) and abnormal cardiac muscle exercise score in the infarct region were significantly increased in the AMI-B than in the SC group that were significantly reversed in the AMI-M group, whereas the left ventricular ejection function by each month (from 1 to 5) displayed an opposite pattern of MSS among the groups (all p < 0.001). By 5 months, histopathological findings of infarct and fibrosis areas and isolectin-B4 exhibited an identical pattern, whereas the cellular expressions of troponin-I/troponin-T/von Willebrand factor exhibited an opposite pattern of MSS among the groups (all p < 0.001). The ST-segment resolution (>80%) was significantly earlier (estimated after 6-h AMI) in the AMI-M group than in the AMI-B group (p < 0.001). The protein expressions of inflammation (IL-1β/TNF-α/NF-κB)/oxidative stress (NOX-1/NOX-2/oxidized protein)/apoptosis (cleaved caspase-3/cleaved PARP)/DNA damage (γ-H2AX) displayed an identical pattern to MSS among the groups, whereas the protein expressions of angiogenesis factors (SDF-1α/VEGF) were significantly and progressively increased from SC, AMI-B, to AMI-M groups (all p < 0.001). CONCLUSION: Early intra-LAD transfusion of OmniMSC treatment effectively reduced the infarct size and preserved LV function in porcine STEMI. Frontiers Media S.A. 2023-03-29 /pmc/articles/PMC10091140/ /pubmed/37063964 http://dx.doi.org/10.3389/fcvm.2023.1153428 Text en © 2023 Chen, Hou, Chen, Shen, Lin, Wu, Lin, Liao, Huang, Yang, Li and Yip. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Chen, Wannhsin
Hou, Chun-Hsiang
Chen, Yi-Ling
Shen, Hsin-Hsin
Lin, Chen-Hsuan
Wu, Cheng-Yi
Lin, Meng-Hsueh
Liao, Chih-Ching
Huang, Jun-Jae
Yang, Chi-Yu
Li, Yi-Chen
Yip, Hon-Kan
Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial
title Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial
title_full Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial
title_fullStr Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial
title_full_unstemmed Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial
title_short Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial
title_sort safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in stemi of lee-sung pigs—a preclinical study for supporting the feasibility of the omnimsc-ami phase i clinical trial
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091140/
https://www.ncbi.nlm.nih.gov/pubmed/37063964
http://dx.doi.org/10.3389/fcvm.2023.1153428
work_keys_str_mv AT chenwannhsin safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT houchunhsiang safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT chenyiling safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT shenhsinhsin safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT linchenhsuan safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT wuchengyi safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT linmenghsueh safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT liaochihching safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT huangjunjae safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT yangchiyu safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT liyichen safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial
AT yiphonkan safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial